Keywords Cloud

Research Outputs

Co-authors[TOP 5]

WANG RUIBING ASSOCIATE PROFESSOR
Title : ASSOCIATE PROFESSOR
PROGRAMME DIRECTOR (STATE KEY LABORATORY)
Institute: Institute of Chinese Medical Sciences
Research Fields: Supramolecular Pharmaceutics/Medicine;Supramolecular Biomaterials;Radiopharmaceuticals (and Radioactive/Heavy Elements Analysis and Control)
Contact email: rwang@umac.mo
Notes: Dr. Ruibing Wang has multidisciplinary background and experience in Organic Chemistry, Supramolecular Chemistry/Materials, Radiopharmaceuticals and Interventional Medicine R&D. During his PhD studies at Queen’s University, he was among the earliest group of researchers to look into a group of novel macrocyclic molecules, cucurbiturils, and their supramolecular encapsulation of various guest molecules including drug molecules for stability and water-solubility enhancement. Due to his excellent thesis work, he was nominated for “Governor General Gold Medal” and subsequently received “Queen’s University Outstanding Thesis in Physical Sciences”. After graduation with PhD study and a brief postdoctoral stay at Queen’s, he moved to the Steacie Institute for Molecular Sciences at the National Research Council (NRC) of Canada as an Associate Research Officer for about two years, where he worked on fluorescent quantum dots development and studied their various applications including bioimaging. He was subsequently invited to join BTG International (Canada) as a Senior Scientist, where he had led various innovation and applied research projects around radiopharmaceuticals and interventional medicine development. Since late 2014, he has joined the University of Macau as an Assistant Professor in Pharmaceutical Sciences. He has been affiliated with the Editorial Office of Chinese Medicine (SCI-index journal, co-owned by ISCM and UM) as Deputy Director since 2016. His research interest has been mainly focused on supramolecular pharmaceutics and supramolecular medicine, and smart biomaterials, as well as radiopharmaceutical sciences. So far, he has published more than 110 peer-reviewed SCI papers with a total citation of around 2000 times and an H-index of 25 (Google Scholar).
WANG RUIBING

Research Contents

  • We are interested in supramolecular interactions between macrocyclic molecules (such as cucurbiturils, cyclodextrins, pillararenes and calixarenes) and synthetic/natural drugs, with intentions to explore the beneficial roles of these macrocycles as emerging excipients for enhancing water solubility, stability, transcellular activity, and ultimately therapeutic efficacy with reduced side effects of guest medicines. In many cases, these macrocycles may act as reversal agents (or antidotes) towards toxic effects of guest drugs. Our collaborators include colleagues here at UM, as well as external scientists from Canada, France, USA, Hong Kong and mainland China.
  • Supramolecular Biomaterials
    We intend to incorporate high potency ingredients (e.g. particularly those of natural products) into stimuli-responsive supramolecularly self-assembled materials for various biomedical applications such as precision medicine, controlled drug release and interventional medicine for targeted therapy. These material matrices include natural polysaccharides, natural and synthetic macrocycles and their derivatives. By placing real-world clinical applications as our study aim, we work closely with scientists and clinicians in the region and around the world.
  • Biomimetic Drug Delivery
    by Nature and ancient principles of Chinese medicine, we are highly interested in developing biomimetic drug delivery systems, particularly those based on supramolecular assembly, for improved therapeutics in a variety of diseases, such as inflammatory diseases, infections and cancers.

Biography

Dr. Ruibing Wang has multidisciplinary background and experience in Organic Chemistry, Supramolecular Chemistry, Nanomaterials, Pharmaceutics, Radiopharmaceuticals and Interventional Medicine R&D. During his PhD studies at Queen’s University, he was among the earliest group of researchers to look into a group of novel macrocyclic molecules, cucurbiturils, and their supramolecular encapsulation of various guest molecules including drug molecules for stability and water-solubility enhancement. Due to his excellent thesis work, he was nominated for “Governor General Gold Medal” and received “Queen’s University Outstanding Thesis in Physical Sciences”. After graduation with PhD study and a brief postdoctoral stay at Queen’s, he moved to the Steacie Institute for Molecular Sciences at the National Research Council (NRC) of Canada as a Research Associate (later promoted to Associate Research Officer) for about two years, where he worked on fluorescent quantum dots development and studied their various applications including bioimaging. He subsequently joined BTG International (Canada) as a Senior Scientist, where he had led various innovation and applied research projects around radiopharmaceuticals and interventional medicine development. Since late 2014, he has joined the University of Macau (UM) as an Assistant Professor in Pharmaceutical Sciences and was promoted to Associate Professor in 2019. His research interest has been mainly focused on supramolecular pharmaceutics, supramolecular medicine, and smart drug delivery systems. He is also interested in radiopharmaceutical sciences and molecular imaging. Since joining UM, he has received several prestigious awards including Macau Science and Technology Awards (3rd Prize, Natural Science Award) in 2018, Faculty-Level Academic Award in 2018, Faculty-Level Best Teacher Award in 2019, UM Teaching Excellence Award in 2019, and China Macrocyclic Arenes and Supramolecular Chemistry Rising Star Award in 2019. So far, he has published more than 130 peer-reviewed SCI papers with a total citation of over 2600 times and an H-index of 29 (Google Scholar).

Research Outputs

Items Views Downloads TC[WOS] TC[CSCD] H-index
Sort: